All articles by  

  1. FDA approves Novartis’ Adakveo for sickle cell disease patients

    The US Food and Drug Administration (FDA) has approved Novartis’ Adakveo (crizanlizumab) to mitigate the frequency of vaso-occlusive crises (VOCs),…
    Read More…

    18 Nov
  2. Sarepta and StrideBio sign gene therapy development deal

    Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight…
    Read More…

    15 Nov
  3. FDA grants priority review to tumour drug selumetinib

    The US Food and Drug Administration (FDA) has awarded priority review status for AstraZeneca and MSD (Merck)’s selumetinib to treat…
    Read More…

    15 Nov
  4. Bayer to invest $100m for alliance with Dewpoint Therapeutics

    Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for…
    Read More…

    15 Nov
  5. WHO announces pilot for insulin prequalification

    The World Health Organization (WHO) has launched a pilot programme for insulin prequalification to boost access to diabetes treatment. Under…
    Read More…

    14 Nov
  6. Boehringer-Lilly’s diabetes drug fails to receive FDA panel votes

    The US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted against Boehringer Ingelheim and…
    Read More…

    14 Nov
  7. Merck acquires Calporta Therapeutics for $576m

    Merck (MSD) has acquired small molecule therapies developer Calporta Therapeutics for a total consideration of approximately $576m. The terms of…
    Read More…

    14 Nov
  8. US researchers launch neurohub for brain disease therapies

    US researchers have launched a research network, Weill Neurohub, to develop treatments for brain and nervous system diseases and disorders….
    Read More…

    13 Nov
  9. Skyhawk and Celgene expand alliance to identify new drug targets

    Skyhawk Therapeutics has formed a second alliance with an affiliate of Celgene to identify drug targets in autoimmune diseases, oncology…
    Read More…

    13 Nov
  10. Vaximm partners with NEC on neoantigen cancer vaccines

    Biotech company Vaximm has partnered with technologies provider NEC Corporation to develop personalised neoantigen cancer vaccines. The companies signed strategic…
    Read More…

    13 Nov
Close
Close
Close

Go Top